Envisagenics and Boehringer Ingelheim signed a $1 billion-plus collaboration deal to develop treatments for hard-to-treat cancers, the companies announced Tuesday.
Why it matters: The deal underscores Big Pharma's appetite for AI-powered drug discovery platforms that can uncover targets traditional approaches may miss.
